Short Interest in Inogen, Inc. (NASDAQ:INGN) Drops By 6.2%

Inogen, Inc. (NASDAQ:INGN - Get Free Report) saw a large drop in short interest in the month of January. As of January 15th, there was short interest totalling 714,200 shares, a drop of 6.2% from the December 31st total of 761,300 shares. Based on an average daily trading volume, of 187,000 shares, the short-interest ratio is currently 3.8 days.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. StockNews.com cut Inogen from a "buy" rating to a "hold" rating in a report on Friday, December 20th. Needham & Company LLC reiterated a "hold" rating on shares of Inogen in a report on Thursday, January 30th.

Hedge Funds Weigh In On Inogen

Institutional investors have recently added to or reduced their stakes in the company. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Inogen by 312.5% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 174,625 shares of the medical technology company's stock worth $1,694,000 after acquiring an additional 132,287 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Inogen by 2.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 896,106 shares of the medical technology company's stock worth $8,692,000 after purchasing an additional 23,891 shares in the last quarter. Barclays PLC grew its stake in shares of Inogen by 72.9% in the 3rd quarter. Barclays PLC now owns 55,508 shares of the medical technology company's stock worth $539,000 after buying an additional 23,398 shares during the last quarter. B. Riley Wealth Advisors Inc. bought a new position in Inogen during the 2nd quarter valued at approximately $457,000. Finally, Geode Capital Management LLC boosted its holdings in Inogen by 1.1% in the third quarter. Geode Capital Management LLC now owns 554,191 shares of the medical technology company's stock worth $5,377,000 after acquiring an additional 5,921 shares in the last quarter. Institutional investors own 89.94% of the company's stock.

Inogen Price Performance

Inogen stock traded down $0.11 during trading hours on Wednesday, reaching $11.85. The stock had a trading volume of 230,091 shares, compared to its average volume of 251,068. The company has a fifty day simple moving average of $9.92 and a 200-day simple moving average of $10.17. The stock has a market cap of $282.27 million, a PE ratio of -5.27 and a beta of 1.02. Inogen has a 52 week low of $5.82 and a 52 week high of $13.33.

Inogen (NASDAQ:INGN - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The medical technology company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.51) by $0.26. The business had revenue of $88.83 million for the quarter, compared to the consensus estimate of $83.68 million. Inogen had a negative net margin of 15.89% and a negative return on equity of 27.38%. During the same period in the previous year, the firm earned ($1.97) EPS. Research analysts predict that Inogen will post -1.73 earnings per share for the current fiscal year.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.